Archives of Clinical Infectious Diseases

Published by: Kowsar

Extensively Drug-Resistant Tuberculosis: A Review Article

Payam Tabarsi 1 , 2 , * and Masoud Mardani 3
Authors Information
1 Clinical TB and Epidemiology Research Center (NRITLD), University of Medical Sciences, Tehran, IR Iran
2 Mycobacteriology Research Center (NRITLD), University of Medical Sciences, Tehran, IR Iran
3 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Clinical Infectious Diseases: July 9, 2012, 7 (3); 81-4
  • Published Online: July 2, 2012
  • Article Type: Review Article
  • Received: April 6, 2012
  • Revised: April 28, 2012
  • Accepted: May 4, 2012
  • DOI: 10.5812/archcid.14773

To Cite: Tabarsi P, Mardani M. Extensively Drug-Resistant Tuberculosis: A Review Article, Arch Clin Infect Dis. 2012 ; 7(3):81-4. doi: 10.5812/archcid.14773.

Copyright © 2012, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Clinical Course
3. Treatment
4. Conclusions
  • 1. Christopher J, Lettieri MD. The Emergence and Impact of Extensively Drug-Resistant Tuberculosis.
  • 2. Keshavjee S, Farmer PE. Picking up the pace-scale-up of MDR tuberculosis treatment programs. N Engl J Med. 2010; 363(19): 1781-4[DOI][PubMed]
  • 3. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. 2010;
  • 4. XDR-TB: extensively drug resistant tuberculosis. WHO; 2012;
  • 5. Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis. 2009; 9(1): 19-30[DOI][PubMed]
  • 6. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemoth. 2002; 46(2): 267-74
  • 7. Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med. 2007; 13(3): 295-8[DOI][PubMed]
  • 8. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med. 2004; 10(10): 1111-6[DOI][PubMed]
  • 9. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547): 1575-80[DOI][PubMed]
  • 10. Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis. 2006; 43(7): 841-7[DOI][PubMed]
  • 11. Dye C, Williams BG. Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci USA. 2000; 97(14): 8180-5[DOI][PubMed]
  • 12. Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? Proc Biol Sci. 2001; 268(1462): 45-52[DOI][PubMed]
  • 13. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE 3rd, Stover CK. Compensatory abpc gene experession in Isoniazid- resistant in mycobacterium tuberculosis . Sci. 1996; 272(5268): 1649-3
  • 14. Cohen T, Becerra MC, Murray MB. Isoniazid resistance and the future of drug-resistant tuberculosis. Microb Drug Resist. 2004; 10(4): 280-5[DOI][PubMed]
  • 15. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol. 2005; 5(10): 819-26[DOI][PubMed]
  • 16. Lemus D, Martin A, Montoro E, Portaels F, Palomino JC. Rapid alternative methods for detection of rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2004; 54(1): 130-3[DOI][PubMed]
  • 17. Miotto P, Piana F, Cirillo DM, Migliori GB. Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2008; 46(1): 393-4[DOI][PubMed]
  • 18. Holtz JH, Riekstina V, Zarovska E, Laserson KF, Wells CD, Leimane V. Extreme drug- resistance and treatment outcome under dots-plus, Latvia, 2000-2002. Int J tuberc lung Dis. 2005;
  • 19. Masjedi MR, Tabarsi P, Baghaei P, Jalali S, Farnia P, Chitsaz E, et al. Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. Int J Infect Dis. 2010; 14(5)-402[DOI][PubMed]
  • 20. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007; 45(10): 1290-5[DOI][PubMed]
  • 21. Tabarsi P, Chitsaz E, Baghaei P, Shamaei M, Farnia P, Marjani M, et al. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Microb Drug Resist. 2010; 16(1): 81-6[DOI][PubMed]
  • 22. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007; 13(5): 780-2[DOI][PubMed]
  • 23. Monedero I, Caminero JA. MDR-/XDR-TB management: what it was, current standards and what is ahead. Expert Rev Respir Med. 2009; 3(2): 133-45[DOI][PubMed]
  • 24. Guidelines for the programmatic management of drug-resistant tuberculosis. 2006;
  • 25. Yew WW, Leung CC. Management of multidrug-resistant tuberculosis: Update 2007. Respirology. 2008; 13(1): 21-46[DOI][PubMed]
  • 26. Dhingra VK, Rajpal S, Mittal A, Hanif M. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc. 2008; 55(1): 15-21[PubMed]
  • 27. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008; 359(6): 563-74[DOI][PubMed]
  • 28. Coker RJ. Review: multidrug-resistant tuberculosis: public health challenges. Trop Med Int Health. 2004; 9(1): 25-40[PubMed]
  • 29. Blower S, Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect Dis. 2007; 7(7): 443[DOI][PubMed]
  • 30. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367(16): 1508-18[DOI][PubMed]
  • 31. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest. 2009; 136(2): 420-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments